Stockreport

ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis

CONTRAVIR PHARMACEUTICALS INC  (CTRV) 
US:NASDAQ Investor Relations: ir.contravir.com/investor-relations
PDF EDISON, N.J., June 06, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic dr [Read more]